Skip to main navigation Skip to search Skip to main content

DESIGNATE: A T cell phenotype signature driven dose finding study with siplizumab in type 1 diabetes mellitus

Project: Research

Project Details

StatusFinished
Effective start/end date02/1/23 → 01/31/26

Funding

  • National Institute of Allergy & Infectious Disease: $41,920.40